Immunic appoints biopharmaceutical executive Jon Congleton to board
Proactiveinvestors NA· 2026-03-31 12:55
Group 1 - The content provided by the Company is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities [1] - The Company receives annual cash compensation of up to $25,000 for publishing services rendered on behalf of Immunic Inc [2]
Rotate your European portfolio to prepare for stagflation risk, Goldman Sachs says
Yahoo Finance· 2026-03-31 12:55
Core Viewpoint - The macroeconomic landscape has shifted due to rising geopolitical tensions, increasing the likelihood of stagflation in Europe, which is not fully priced into the market [1] Group 1: Market Performance - Major European stock markets have experienced significant sell-offs since the onset of the Iran war, with key indexes like the Euro Stoxx 50 and Stoxx 600 dropping an average of 2.5% during the first full trading session following US escalation [3] - By late March 2026, benchmark European equity indexes had fallen between 4% and 6% as the conflict continued [3] Group 2: Economic Impact - Europe's heavy reliance on imported energy has exacerbated the impact of the conflict, with wholesale natural gas prices increasing by 35% and Brent crude oil prices surging approximately 50% to $110 per barrel [6] - The rise in oil prices has led to inflation reaching multiyear highs in countries like Spain and Germany, raising concerns that the European Central Bank may need to delay interest rate cuts [7] Group 3: Sector Performance - Defensive sectors such as telecom and consumer staples are expected to outperform during stagflation, while consumer discretionary stocks are likely to lag [1] - Defense contractor stocks are rising due to anticipated increases in military spending, whereas traditional banking and industrial sectors, including Deutsche Bank, Siemens, and Schneider Electric, have seen significant declines due to rising sovereign yields and weakening manufacturing momentum [7] - Deutsche Bank shares have dropped 20% in the past month alone [8]
LPL Financial Welcomes Five Star Wealth Planning
Globenewswire· 2026-03-31 12:55
Core Insights - LPL Financial LLC has welcomed financial advisor Tasha Coleman, founder of Five Star Wealth Planning, to its broker-dealer and Registered Investment Advisor platform, managing approximately $185 million in advisory, brokerage, and retirement plan assets [1][7] Company Overview - LPL Financial Holdings Inc. is one of the fastest-growing wealth management firms in the U.S., supporting over 32,000 financial advisors and approximately 1,200 financial institutions, with around $2.4 trillion in brokerage and advisory assets for about 8 million Americans [6] Advisor Transition - Tasha Coleman brings over 20 years of experience in the industry, focusing on retirement preparation and wealth transfer planning, emphasizing a relational and education-driven approach [2][3] - The transition to LPL is described by Coleman as centered on enhancing client relationships while leveraging superior technology and cybersecurity protections [3][4] Technology and Innovation - Coleman highlighted LPL's advanced technology and commitment to innovation as key factors in her decision to join, stating that it is essential for aligning clients with a firm that prioritizes the advisor-client relationship [4] - LPL's investment in technology and cybersecurity is seen as a significant advantage for advisors and their clients [4] Community Focus - Coleman expressed that the transition allows Five Star Wealth Planning to continue serving multigenerational families while remaining rooted in their community [4] - The firm aims to maintain a boutique feel with the resources of a larger firm, reinforcing their commitment to personalized service [3][4] Leadership Perspective - Scott Posner, managing director of business development at LPL, praised Coleman's dedication to client education and personalized planning, aligning with LPL's mission to empower advisors [4]
NYSE Content Update: A Sweet Time at the NYSE as Hershey Hosts its Investor Day
Prnewswire· 2026-03-31 12:55
Group 1 - Hershey (NYSE: HSY) is hosting its 2026 Investor Day, highlighting its growth strategies and marketing initiatives [3][4] - The New York Stock Exchange (NYSE) provides daily pre-market updates, offering insights into market conditions before trading begins [2][4] - Dimensional Fund Advisors is celebrating the launch of its new ETFs, indicating ongoing innovation in the investment management sector [3][4] Group 2 - The average price of gas in the U.S. has surpassed $4 per gallon, which may impact consumer spending and market dynamics amid geopolitical tensions [4] - Senator Mike Rounds (R-SD) emphasizes the permanence of AI in various sectors, including its role in cybersecurity, reflecting the growing importance of technology in business [4]
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Globenewswire· 2026-03-31 12:55
Core Insights - Ernexa Therapeutics is advancing its lead product candidate ERNA-101 towards a first-in-human clinical trial for platinum-resistant ovarian cancer, with an IND submission expected in Q3 2026 and trial initiation planned for Q4 2026 [1][2][14] - The company has reported significant preclinical data showing durable tumor regressions and prolonged survival in ovarian cancer models when ERNA-101 is combined with PD-1 blockade, indicating its potential as a foundational immunotherapy platform [3][8] - Ernexa is also developing ERNA-201, an engineered anti-inflammatory therapy targeting autoimmune diseases, alongside the advancement of ERNA-101 [5][12] Company Progress - Ernexa has streamlined operations, reducing general and administrative expenses by approximately 61% year over year while maintaining focus on core programs [9] - The company completed Proof of Principle studies for both ERNA-101 and ERNA-201 and successfully held a Pre-IND meeting with the FDA for ERNA-101 [9][10] Upcoming Milestones - Key milestones include the completion of ERNA-101 clinical manufacturing process development in Q2 2026, IND-enabling preclinical studies in Q3 2026, and the initiation of the first-in-human Phase 1 clinical study in Q4 2026 [14] - Initial clinical data readout from ERNA-101 is expected in the first half of 2027, with advancement into Phase 2 trials anticipated in the second half of 2027 [14]
Stack Capital Group Inc. Closes Best Efforts Financing for Total Gross Proceeds of $8,750,000
Globenewswire· 2026-03-31 12:54
Core Viewpoint - Stack Capital Group Inc. has successfully closed its private placement, the LIFE Offering, raising gross proceeds of $8,750,000 by issuing 466,666 units at a price of $18.75 per unit [1][2]. Group 1: Offering Details - The LIFE Offering was led by Canaccord Genuity Corp. as the lead agent and sole bookrunner, with a syndicate of agents including Raymond James Ltd., TD Securities Inc., and RBC Capital Markets [2]. - A concurrent private placement is expected to close around April 10, 2026, with conditional approval from the Toronto Stock Exchange for the listing of the Unit Shares and Warrants [3]. - Each unit consists of one common share and one-quarter of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $23.00 for 24 months [4]. Group 2: Use of Proceeds and Fees - The net proceeds from the LIFE Offering will be utilized for investments in line with the company's investment principles and for general corporate and working capital purposes [6]. - The company paid a cash fee of 5.0% of the gross proceeds to the agents and a corporate finance fee of $100,000 to the lead agent upon closing [6]. Group 3: Company Overview - Stack Capital Group Inc. is an investment holding company focused on investing in equity, debt, and other securities of growth-to-late-stage private businesses, providing shareholders with exposure to a diversified private investment portfolio [8]. - The company aims to maximize long-term performance through a portfolio of high-growth businesses that are not widely available to most Canadian investors [8].
AppLovin Stock's 40% Slide Called 'Out Of Step' With Fundamentals
Investors· 2026-03-31 12:52
Core Viewpoint - AppLovin's stock has experienced a significant decline, losing 14% in March and nearly 45% year-to-date, which analysts believe is inconsistent with the company's strong fundamentals [1][2]. Company Performance - Evercore ISI analyst Robert Coolbrith maintains an outperform rating with a price target of 750 for AppLovin, suggesting that the recent stock price drop does not reflect the company's business strength [2]. - AppLovin's current enterprise value is at 14.6 times its expected 2027 adjusted earnings, indicating a favorable entry point for investors [3]. - The company's software aids mobile app developers in user acquisition and advertising sales, with positive feedback from gaming advertisers indicating continued growth in wallet share for AppLovin's ad platform [3]. Market Analysis - AppLovin is noted for having one of the largest discrepancies between current stock prices and median price targets among S&P 500 stocks, with an average target price of 651.78, implying a potential 75% upside from recent closing prices [4]. - Analysts from Needham have also reiterated a buy rating with a price target of 700, citing positive trends in AppLovin's e-commerce advertising [4]. Stock Volatility and Concerns - AppLovin's stock has seen a decline of 44% this year, despite a 108% increase last year and over 1,000% growth from the start of 2024 through the end of last year [5]. - Concerns affecting the stock include competition from AI tools and broader macroeconomic issues, such as rising oil costs due to geopolitical tensions [5]. - The company has faced scrutiny from short-seller reports questioning its business practices and data measurement methods, which AppLovin has disputed [6]. Regulatory Scrutiny - AppLovin's shares fell following reports of an SEC investigation into its data collection practices, which is still ongoing [7]. - Despite reporting strong fourth-quarter results with adjusted earnings per share of $3.24 (88% year-over-year growth) and revenue of $1.66 billion (66% year-over-year growth), the stock slid 18% post-announcement [7]. Ratings and Performance Metrics - AppLovin holds an IBD Composite Rating of 52 out of 99, indicating room for improvement as top growth stocks typically have ratings of 90 or higher [8]. - The stock has exhibited volatility, with an average true range of 6.03, suggesting significant price movements that could trigger sell rules [9].
Newmont: Top Gold Miner Trading At 25% Discount
Seeking Alpha· 2026-03-31 12:52
Core Viewpoint - Newmont Mining has shown significant stock performance, increasing from approximately $48 in May 2023 to around $102, representing a 109% rise [1] Company Performance - The stock price of Newmont Mining (NEM) has appreciated significantly, indicating strong market confidence and potential growth opportunities [1] Investment Perspective - The previous rating of Newmont as a "Buy" reflects a positive outlook on the company's future performance and investment potential [1]
Morning Market Movers: APLS, PEPG, CDT, PHR See Big Swings
RTTNews· 2026-03-31 12:52
Core Viewpoint - Premarket trading is showing significant activity with notable price movements in various stocks, indicating potential trading opportunities before the market opens [1]. Premarket Gainers - Apellis Pharmaceuticals, Inc. (APLS) is up 137% at $40.61 - Polar Power, Inc. (POLA) is up 19% at $2.33 - Allbirds, Inc. (BIRD) is up 16% at $3.48 - Affinity Bancshares, Inc. (AFBI) is up 14% at $22.47 - Scholar Rock Holding Corporation (SRRK) is up 11% at $48.00 - Artelo Biosciences, Inc. (ARTL) is up 8% at $9.45 - Brand Engagement Network, Inc. (BNAI) is up 8% at $8.74 - Wave Life Sciences Ltd. (WVE) is up 7% at $7.10 - Veru Inc. (VERU) is up 7% at $2.29 - Prairie Operating Co. (PROP) is up 7% at $2.14 [3]. Premarket Losers - PepGen Inc. (PEPG) is down 53% at $1.98 - CDT Equity Inc. (CDT) is down 25% at $7.00 - Phreesia, Inc. (PHR) is down 24% at $8.59 - J.Jill, Inc. (JILL) is down 15% at $12.60 - Cyabra Strategy Ltd. (CYAB) is down 14% at $2.04 - T1 Energy Inc. (TE) is down 13% at $4.84 - ImageneBio, Inc. (IMA) is down 13% at $4.33 - Satellogic Inc. (SATL) is down 5% at $4.70 - Bolt Biotherapeutics, Inc. (BOLT) is down 5% at $4.00 - BioNexus Gene Lab Corp. (BGLC) is down 5% at $2.20 [4].
How to get a debt consolidation loan in 6 steps
Yahoo Finance· 2026-03-31 12:52
Core Insights - Understanding how to obtain a debt consolidation loan and exploring alternatives can enhance financial stability and support long-term financial objectives [2] Group 1: Credit Score Importance - The credit score is the most significant factor in securing a debt consolidation loan, with a score of at least 740 typically required for competitive interest rates [4] - For individuals with low credit scores due to maxed-out credit cards, exploring options for debt consolidation with bad credit is advisable, although it may require more effort to find competitive rates [3][5] Group 2: Debt Management - Listing all debts, including amounts owed, interest rates, and minimum payments, is essential for determining the total loan amount needed for consolidation [6] - Calculating current monthly payments helps assess whether a debt consolidation loan will result in lower monthly costs [6] Group 3: Benefits of Debt Consolidation - A debt consolidation loan can improve credit scores by reducing the risk of missed payments through the simplification of multiple debts into one fixed-rate loan [7] - Paying off credit card debt directly lowers the credit utilization ratio, which can lead to a quick boost in credit scores if future credit card use is avoided [7] Group 4: Loan Application Process - Before applying for a debt consolidation loan, it is crucial to check the credit score, determine the desired consolidation amount, and perform necessary calculations [8] - Comparing lenders is vital to select a debt consolidation loan that either lowers monthly payments or reduces the total interest paid [8]